Circulating tumor cells and circulating tumor DNA - Abstract

University Medical Center, Saint-Eloi Hospital, Institute of Research in Biotherapy, Laboratory of Rare Human Circulating Cells, Montpellier, France.

University Medical Center, Laboratory of Cell and Hormonal Biology, Arnaud de Villeneuve Hospital, Montpellier, France; University Institute of Clinical Research UM1 - EA2415 - Epidemiology, Biostatistics & Public Health.

 

 

Solid tumors derived from epithelial tissues (carcinomas) are responsible for 90% of all new cancers in Europe, and the main four tumor entities are breast, prostate, lung, and colon cancer. Present tumor staging is mainly based on local tumor extension, metastatic lymph node involvement, and evidence of overt distant metastasis obtained by imaging technologies. However, these staging procedures are not sensitive enough to detect early tumor cell dissemination as a key event in tumor progression. Many teams have therefore focused on the development of sensitive assays that allow the specific detection of single tumor cells or small amounts of cell-free tumor DNA in the peripheral blood of cancer patients. These methods allow the detection and characterization of early metastatic spread and will provide unique insights into the biology of metastatic progression of human tumors, including the effects of therapeutic interventions.

Written by:
Alix-Panabières C, Schwarzenbach H, Pantel K.   Are you the author?

Reference: Annu Rev Med. 2011 Jan 26. Epub ahead of print.
doi: 10.1146/annurev-med-062310-094219

PubMed Abstract
PMID: 22053740

UroToday.com Prostate Cancer Section